# Spinous Process-Splitting Laminectomy Versus Conventional Laminectomy: A Short-Term Outcome Study

**Authors:** Ahmed K Basha, Hesham Radwan, Abdelmaksod Mohammed Mousa, Ahmed Nagaty, Abdelrahman Bakry, Eslam Hussein, Mohamed Ashraf Mahmoud, Mohammed Eid

PMC · DOI: 10.7759/cureus.102648 · Cureus · 2026-01-30

## TL;DR

This study compares two spine surgery techniques and finds that one causes less pain, less blood loss, and faster recovery.

## Contribution

The study provides new evidence that spinous process-splitting laminectomy is a better short-term alternative to conventional laminectomy.

## Key findings

- SPSL had less blood loss, shorter operative time, and less postoperative pain compared to conventional laminectomy.
- Patients in the SPSL group returned to daily activities faster than those in the conventional group.
- SPSL showed better functional outcomes and lower disability scores at six months post-surgery.

## Abstract

Background: Symptomatic lumbar spine stenosis (LSS) is a common spine degenerative disease often associated with back pain and neurogenic claudication pain. Laminectomy is a widely performed procedure in treating LSS, but it can lead to approach-related morbidity due to iatrogenic paraspinal muscle injury. Spinous process-splitting laminectomy (SPSL) is a muscle-preserving laminectomy technique that has been reported to provide superior functional outcomes and less postoperative pain.

Methods: This retrospective comparative study evaluated the conventional laminectomy (CL) and SPSL techniques regarding operative time, blood loss, postoperative pain, disability indices, and time to return to daily activities.

Results: A total of 27 patients were included in the study. The mean age of the participants was 62.5 ± 7.8 years, with 13 patients in the CL group and 14 patients in the SPSL group. The average intraoperative blood loss was less in the SPSL group (123.21 ± 54.12 ml) compared to the CL group (188.46 ± 79.46 ml). The mean operative time was 67.86 ± 33.27 min in the SPSL group and 87.69 ± 32.44 min in the CL group. The mean immediate postoperative low back pain on the Visual Analog Scale (VAS) at day one was 2.8 ± 0.6 for the CL group and 2.0 ± 0.0 for the SPSL group (p-value = 0.001). At six months, the mean postoperative low back pain on VAS was 0.77 ± 0.44 for the CL group and 0.21 ± 0.43 for the SPSL group (p-value = 0.012). The average Oswestry Disability Index (ODI) score at six months postoperatively was 2.21 ± 0.43 for the SPSL group and 4.38 ± 4.73 for the CL group (p-value = 0.001). The average time to return to normal activities of daily living was 2.07 ± 0.27 days in the SPSL group, much less than 6.77 ± 4.6 days in the CL group (p-value < 0.01).

Conclusion: SPSL represents a minimally invasive alternative to CL, with significant reductions in operative time and intraoperative blood loss. It also results in less postoperative pain and better functional outcomes, enabling an earlier return to daily activities.

## Full-text entities

- **Diseases:** motor weakness (MESH:D018908), spinal tumors (MESH:D009369), Postoperative pain (MESH:D010149), FBSS (MESH:D055111), degenerative spondylolisthesis (MESH:D013168), blood loss (MESH:D016063), nerve root injury (MESH:D011843), Degenerative lumbar stenosis (MESH:C563613), hypoesthesia (MESH:D006987), wound infections (MESH:D014946), deep venous thrombosis (MESH:D020246), peripheral vascular disease (MESH:D016491), muscle fibrosis (MESH:D005355), spine degenerative disease (MESH:D019636), spine (MESH:D016135), degenerative scoliosis (MESH:D012600), muscle atrophy (MESH:D009133), muscle (MESH:D019042), back pain (MESH:D001416), fractures (MESH:D050723), blood (MESH:D006402), leg pain (MESH:D010146), spinal instability (MESH:D043171), neurologic deficits (MESH:D009461), canal stenosis (MESH:D003251), neurogenic claudication (MESH:D007383), prolapsed disc disease (MESH:D007405), low back pain (MESH:D017116), bleeding (MESH:D006470), postoperative delirium (MESH:D000071257), CL (MESH:C000711512), pars fractures (MESH:D015868), muscle injury (MESH:D009135)
- **Chemicals:** CL (-), polydioxanone (MESH:D016687), PDS (MESH:D010165)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950225/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12950225/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950225/full.md

---
Source: https://tomesphere.com/paper/PMC12950225